Myriad to Announce Fiscal First Quarter 2016 Financial Results on November 3, 2015

SALT LAKE CITY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal first-quarter 2016 and provide a business update following the close of market on Tuesday, November 3, 2015.

The Company also will host a conference call at 4:30 p.m. ET on November 3, 2015 to discuss the financial results. Participating on the call from Myriad will be Mark C. Capone, president and chief executive officer and Bryan Riggsbee, chief financial officer.

To listen to the call, interested parties in the United States may dial 800-706-9302 or +1 303-223-4366 for international callers. All callers will be asked to reference reservation number 21779749.

The conference call also will be available through a live webcast at A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21779749.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where high value diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer markets, diversifying its product portfolio through the introduction of new products and increasing its international contribution. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

CONTACT: Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Source:Myriad Genetics, Inc.